SCIENTIFIC HUB

Follow the evidence.

SCIENTIFIC LITERATURE · MED

Causal Effects Between Antibody-Mediated Immune Responses and Parkinson's Disease: Insights from Genetic Studies.

Cureus · 2026-01-21

DOI: 10.7759/cureus.101998PMID: 41728547

Open accessresearch-article; Journal ArticleOriginal source ↗

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

BackgroundParkinson's disease (PD) is a multifactorial neurodegenerative disorder with a complex etiology. Increasing evidence suggests that antibody-mediated immune responses elicited by prior infectious exposures may contribute to its pathogenesis; however, whether these associations reflect true causal relationships remains unresolved, largely due to confounding and other inherent limitations of observational study designs.MethodologyWe conducted a two-sample Mendelian randomization (MR) analysis to interrogate the causal associations between 46 antibody-mediated immune responses and PD risk, leveraging Genome-wide association study (GWAS) summary statistics for antibody-related traits and PD data from the FinnGen consortium (5,861 cases and 494,487 controls of European ancestry). Independent genetic variants reaching genome-wide significance were selected as instrumental variables. Causal estimates were primarily derived using the inverse-variance weighted approach, with complementary analyses conducted using the weighted median, MR-Egger regression, and both simple and weighted mode methods. Bayesian weighted MR, together with a series of sensitivity analyses, was employed to evaluate the robustness of the findings and interrogate potential heterogeneity and horizontal pleiotropy.ResultsAmong the 46 antibody-mediated immune responses analyzed, two showed statistically significant causal associations with PD after Bonferroni correction. Genetically predicted elevated antibody levels against Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA-1) were significantly associated with an increased risk of PD (odds ratio (OR) = 1.154, 95% confidence interval (CI): 1.098-1.214, P -4). In contrast, genetically predicted seropositivity for anti-polyomavirus 2 IgG was associated with a reduced risk of PD ( OR = 0.897, 95% CI: 0.865-0.930, P -4). Sensitivity analyses revealed no evidence of significant heterogeneity or horizontal pleiotropy.ConclusionsThis MR study offers genetic evidence supporting a potential causal involvement of specific antibody-mediated immune responses in the pathogenesis of PD. Elevated EBNA-1 antibody levels are associated with an increased risk of PD, whereas anti-polyomavirus 2 IgG seropositivity appears to confer a protective effect. These findings provide new insights into the immunological mechanisms underlying PD and underscore the potential of immune-related biomarkers and therapeutic targets.

Scientific assessment

01

Research question

Assess the question within the original study’s scope.

02

Methods & sample

Check the source article for study design and sample details.

03

Key findings

An editorially approved findings summary is not yet published for this record.

04

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.